Lack of association between erythropoietin treatment and risk of depression in patients with end-stage kidney disease on maintenance dialysis: a nationwide database study in Taiwan

BACKGROUND: Patients with end-stage kidney disease (ESKD), have been associated with higher risk of developing depression. Erythropoietin (EPO), frequently used for the treatment of anemia in ESKD patients, has been shown to have neuroprotective and antidepressant effects. In this study, we examined...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Pao-Yen, Li, Lung-Chih, Wang, Liang-Jen, Yang, Yao-Hsu, Hsu, Chih-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940772/
https://www.ncbi.nlm.nih.gov/pubmed/33747426
http://dx.doi.org/10.1177/2040622321995690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940772/
https://www.ncbi.nlm.nih.gov/pubmed/33747426
http://dx.doi.org/10.1177/2040622321995690

Ejemplares similares